Fig. 1.
Constructs design and production of eVLPs expressing SARS-CoV-2 Spike protein. (a) Schematic representation of SARS-COV-2 S plasmid constructs. TM-CTD: Transmembrane cytoplasmic terminal domain. (b) Expression of SARS-CoV-2 S analyzed by Western-blot of SARS-CoV-2 eVLPs and recombinant proteins using a rabbit polyclonal Ab (pAb, upper panel) raised against SARS-CoV-2 RBD (Sinobiological) or COVID-19 convalescent human serum (HuCS, bottom panel). eVLPs produced with Gag plasmid only (Gag eVLPs) and recombinant SARS-CoV-2 S proteins were used as negative and positive controls respectively. (c) Detection of SARS-CoV-2 S by Western-blot (anti-RBD pAb) after overnight incubation at 37 °C with or without PNGase F (New England Biolabs) at 1000 and 2000 Units as indicated. MW: molecular weight ladder, r-S: recombinant native S, r-SP: recombinant prefusion S protein containing a mutated furin cleavage domain (RRAR → GSAS), replacement of 2 proline (KV → PP) and a trimerization domain.
